Multiple Myeloma: Teclistamab with Lenalidomide

We are studying a new treatment combining teclistamab and lenalidomide for patients with newly diagnosed multiple myeloma after stem cell transplant. The aim is to see if this combination works better than lenalidomide alone in maintaining remission.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Lenalidomide Accord
Lenalidomide Accord is a cancer medicine used to treat certain blood cancers, such as multiple myeloma, some lymphomas, and bone marrow disorders.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Lenalidomide
Lenalidomide is a substance that helps treat certain blood cancers by affecting the immune system to stop cancer growth.
Teclistamab
Teclistamab is a substance that helps the immune system recognize and attack multiple myeloma cancer cells.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

7,5 Mg Stada
Cortedal
Ferulinor

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Vorarlberger Krankenhaus-Betriebsgesellschaft mbH
Internal Medicine II, Interne E
Feldkirch, Austria
Medizinische Universitaet Innsbruck
Universitätsklinik für Innere Medizin V
Innsbruck, Austria
Universitaetsklinikum Krems
Molekulare Onkologie/Hämatologie
Krems an der Donau, Austria

Sponsor: European Myeloma Network B.V.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.